CEO, Rines Therapeutics and External Innovation Consultant
University of Utah
Sudhir Sahasrabudhe has 24 years of leadership experience in novel drug discovery (NCE) in Pharmaceutical & Biotechnology industry. He is the CEO of Rines Therapeutics and Research Professor of Medicinal Chemistry at the University of Utah. He is a consultant to the Global External Innovation Group at Merck Serono (EMD Serono). He is a member of the Utah Chapter of American Parkinson's Disease Association (APDA). Dr Sahasrabudhe's primary therapeutic areas of expertise are Oncology, Neuroscience, and inflammation-related diseases. Dr. Sahasrabudhe started his Pharma career at the Lederle Laboratories (now Pfizer) in 1990 and subsequently worked at Aventis (now Sanofi) from 1993 through 2000. As Senior Director of US Biotechnology at Aventis, Dr Sahasrabudhe introduced genomics and proteomics technologies to support the drug discovery projects.He represented Aventis as the founding board member of the Pharma SNP consortium. In year 2000 Dr Sahasrabudhe moved to Myriad Genetics as the Executive VP of R&D. He was the scientific founder, Chief Scientific Officer and member of the board of Myriad Proteomics/ Prolexys from 2002 through 2010. Dr. Sahasrabudhe served as a member of the Board of trustee's at Utah State University Research Foundation (USURF) from 2002-2007 and the member of Board of Associates at MIT Whitehead (2000-2007). He has several issued patents in the area of drug discovery and has authored high profile publications in top-tier peer reviewed journals.